ATE408144T1 - Assays - Google Patents

Assays

Info

Publication number
ATE408144T1
ATE408144T1 AT01977000T AT01977000T ATE408144T1 AT E408144 T1 ATE408144 T1 AT E408144T1 AT 01977000 T AT01977000 T AT 01977000T AT 01977000 T AT01977000 T AT 01977000T AT E408144 T1 ATE408144 T1 AT E408144T1
Authority
AT
Austria
Prior art keywords
assays
bam
agonists
antagonists
rat
Prior art date
Application number
AT01977000T
Other languages
English (en)
Inventor
Sultan Ahmad
Eric Grazzini
Thierry Groblewski
Paolo Lembo
Ralf Schmidt
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of ATE408144T1 publication Critical patent/ATE408144T1/de

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • G01N2500/10Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT01977000T 2000-10-17 2001-10-16 Assays ATE408144T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US24088900P 2000-10-17 2000-10-17

Publications (1)

Publication Number Publication Date
ATE408144T1 true ATE408144T1 (de) 2008-09-15

Family

ID=22908344

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01977000T ATE408144T1 (de) 2000-10-17 2001-10-16 Assays

Country Status (9)

Country Link
US (1) US7270965B2 (de)
EP (1) EP1334362B1 (de)
JP (1) JP2004511806A (de)
AT (1) ATE408144T1 (de)
AU (1) AU2001296150A1 (de)
CA (1) CA2423596A1 (de)
DE (1) DE60135773D1 (de)
ES (1) ES2311551T3 (de)
WO (1) WO2002033416A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004111642A2 (en) * 2003-06-16 2004-12-23 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with sensory neuron-specific g protein-coupled receptor 1 (snsr1)
WO2005003762A2 (en) * 2003-06-17 2005-01-13 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with sensory neuron-specific g protein-coupled receptor 2 (snsr2)
WO2005003763A2 (en) * 2003-06-18 2005-01-13 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with mas related g-protein coupled receptor 3 (mrgx3)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4388236A (en) 1979-08-30 1983-06-14 Hoffmann-La Roche Inc. Enkephalin-like compounds in bovine adrenal medulla
US5367053A (en) 1993-05-19 1994-11-22 Houghten Pharmaceuticals, Inc. Opioid peptide inhibitors
SE9704836D0 (sv) * 1997-12-22 1997-12-22 Astra Pharma Inc Novel receptor
EP1118621A4 (de) 1998-10-01 2003-06-25 Takeda Chemical Industries Ltd Neuartiges g-protein gekoppelter rezeptorprotein und dessen dna
WO2001083555A2 (en) * 2000-05-04 2001-11-08 California Institute Of Technology Pain signaling molecules

Also Published As

Publication number Publication date
JP2004511806A (ja) 2004-04-15
US7270965B2 (en) 2007-09-18
WO2002033416A1 (en) 2002-04-25
AU2001296150A1 (en) 2002-04-29
EP1334362A1 (de) 2003-08-13
DE60135773D1 (en) 2008-10-23
ES2311551T3 (es) 2009-02-16
EP1334362B1 (de) 2008-09-10
CA2423596A1 (en) 2002-04-25
US20050059575A1 (en) 2005-03-17

Similar Documents

Publication Publication Date Title
SG149693A1 (en) Peptides acting as both glp-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use
EA200101177A1 (ru) Производные индола в качестве антагонистов прогестерона
AUPO755097A0 (en) Receptor agonist and antagonist
DE69942753D1 (de) Peptidantagonist von Zonulin und dessen Verwendung
EA200300441A1 (ru) Ассоциация антагониста рецептора св1 и сибутрамина, содержащие их фармацевтические композиции и их применение для лечения ожирения
EA200200646A1 (ru) Соединения мочевины, обладающие активностью антагонистов мускариновых рецепторов
AU5716901A (en) G protein coupled receptor (gpcr) agonists and antagonists and methods of activating and inhibiting gpcr using the same
PT1066380E (pt) Receptor de celula t soluvel
DK1140173T4 (da) Vaskulære endothelcellevækstfaktorantagonister og anvendelser deraf
DK1023074T3 (da) Fremgangsmåder til behandling af psykose forbundet med glucocorticoid-relateret dysfunktion
ATE521599T1 (de) Heterocyclische modulatoren von nukleären rezeptoren
ATE382060T1 (de) Moleküle und verfahren zur inhibierung der freisetzung von kim-1
EA200601517A1 (ru) Нацеливающие пиперидинилсодержащие соединения, селективно связывающие интегрины
DK1411916T3 (da) Fremgangsmåder og materialer til behandling af testosteronmangel hos mænd
TR200102041T2 (tr) Progesteron reseptör bağlama aktif maddeleri olarak ikameli 2-arilimino heterosaykıllar
ATE408144T1 (de) Assays
UA87122C2 (ru) Агонисты рецепторов глюкагонподобного пептида-1, их применение и способ получения
TR199902399T2 (xx) Bir asfalt bile�imi haz�rlamak i�in i�lem.
TR200200357T2 (tr) Yeni integrin reseptör antagonistleri
DK1022636T3 (da) Blandingsarmatur med etgrebsbetjening
NO20006320L (no) Cykliske somatostatin-analoger
DE60231062D1 (de) Y y5-rezeptors
SE9904660D0 (sv) Novel assays
ATE441642T1 (de) Hydantoin derivate mit affinität für somatostatin rezeptoren
DK1095275T3 (da) Endogen, konstitutivt aktiverede G-protein-koblede orphan-receptorer

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties